"
Team:METU-Gene/Collagen Sponge
From 2009.igem.org
(→The release rate of bioactive hEGF from crosslinking collagen sponges ==) |
|||
| Line 7: | Line 7: | ||
the effects of different types of crosslinked collagen | the effects of different types of crosslinked collagen | ||
sponges as platforms for the controlled release of rhEGF. | sponges as platforms for the controlled release of rhEGF. | ||
| + | |||
<br>The microstructure and the drug release rates of collagen | <br>The microstructure and the drug release rates of collagen | ||
sponges were modified through treatment with different | sponges were modified through treatment with different | ||
| Line 13: | Line 14: | ||
concentrations of crosslinking agents and various preparation | concentrations of crosslinking agents and various preparation | ||
conditions. | conditions. | ||
| + | |||
<br>a good correlation was obtained for | <br>a good correlation was obtained for | ||
in vitro release rates of rhEGF using the power model. The | in vitro release rates of rhEGF using the power model. The | ||
Revision as of 10:27, 13 October 2009
The release rate of bioactive hEGF from crosslinking collagen sponges ==
The purpose of this study was to prepare
recombinant human epidermal growth factor (rhEGF)
collagen sponges for topical applications and investigate
the effects of different types of crosslinked collagen
sponges as platforms for the controlled release of rhEGF.
The microstructure and the drug release rates of collagen
sponges were modified through treatment with different
types (glutaraldehyde (GTA), genipin and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC)), different
concentrations of crosslinking agents and various preparation
conditions.
a good correlation was obtained for
in vitro release rates of rhEGF using the power model. The
crosslinked rhEGF collagen sponges showed a successful
delivery of rhEGF in bioactive form to stimulate cell
proliferation.
